{"a": [["Repaglinide with bedtime insulin improves glycaemic control in poorly controlled type 2 diabetes", "2000"], ["Use of the combination of insulin and the prandinal glucose regulator repaglinide in patients with type 2 diabetes mellitus", "2002"], ["Improvement of beta cell function by nateglinide and repaglinide in type 2 diabetic patients: a randomized controlled double blinded and double dummy multicentre study", "2005"], ["Effect of metformin vs repaglinide on postprandial glycaemia, plasma lipoproteins and free fatty acids in non\u2010obese patients with type\u20102 diabetes (T2DM)", "2005"], ["20\u2010week multicentre, prospective, open\u2010label study of the efficacy, safety and applicability of repaglinide as a first line therapy in treating type 2 diabetes patients in Diabetes Centres in Macedonia [Bulgarian]", "2005"], ["Similar improvement in glycemic control with lower risk of hypoglycemia with repaglinide and bedtime NPH insulin compared to twice dally NPH insulin", "2004"], ["Therapy focused on lowering postprandinal glucose, not fasting glucose, may be superior for lowering HbA1c", "2000"], ["Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes", "2001"], ["The postprandial blood glucose level. A new traget for optimising treatment of diabetes mellitus", "2000"], ["A coefficient of agreement for nominal scales", "1960"], ["The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long\u2010Term Complications in Insulin\u2010Dependent Diabetes Mellitus", "1993"], ["Pharmacologic therapy for type 2 diabetes mellitus", "1999"], ["Hyperglycaemia is associated with all\u2010cause and cardiovascular mortality in the Hoorn population: the Hoorn Study", "1999"], ["Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnositc criteria", "1999"], ["Insulinotrophic meglitinide analogues", "2001"], ["Clinical significance, pathogenesis and management of postprandinal hyperglycaemia", "2003"], ["Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up", "1996"], ["Quantifying heterogeneity in a meta\u2010analysis", "2002"], ["Measuring inconsistency in meta\u2010analysis", "2003"], ["Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]", "2005"], ["Oral antihyperglycaemic therapy for type 2 diabetes", "2002"], ["Assessing the quality of reports of randomized clinical trials: Is blinding necessary?", "1996"], ["Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out and commissioning reviews", "2000"], ["Metformin: an update", "2002"], ["Meglitinide analogues in the treatment of type 2 diabetes mellitus", "2000"], ["Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials", "1995"], ["Improvement of insulin resistance by a new insulin secretagogue, nateglinide \u2010 analysis based on the homeostasis model", "2003"], ["Association pf glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35)", "2000"], ["UK Prospective study 16: overview of 6 years therapy of type II diabetes \u2010 a progressive disease", "1995"], ["ABC of diabetes: Cardiovascular disease, hypertension, and lipids", "2003"], ["Insulin resistance and impaired glucose tolerance", "1994"]], "ex": [["Nateglinide (Starlix((R)) effectively lowers HbA(1c), through reductions in post prandial glucose in subjects with type 2 diabetes mellitus", "2002"], ["Repaglinide\u2010metformin combination in the treatment of type 2 diabetes: Comparison between three different combination regimens", "2004"], ["Clinical effects of repaglinide on type 2 diabetes mellitus", "2002"], ["Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal", "2002"], ["Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes", "1999"], ["Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes", "2001"], ["Both nateglinide and metformin sustain HbA(1c) lowering over 52 weeks in drug\u2010naive type 2 diabetes patients", "2001"], ["Oral nateglinide administration improves glycemic control of Type 2 diabetic patients, treated with intermediate\u2010acting insulin", "2001"], ["Safety and efficacy of repaglinide in 281 type 2 diabetic patients with or without renal impairment", "2001"], ["Clinical pharmacokinetics and pharmacodynamics of repaglinide", "2002"], ["Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin", "2000"], ["Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet\u2010treated patients with type 2 diabetes", "2001"], ["Risks/Benefits of achieving HbA1c goals with nateglinide", "2001"], ["Initial combination therapy with nateglinide and metformin is safe and effective", "2003"], ["Nateglinide reduces mean glycemia in diet\u2010 and previously treated type 2 diabetic patients", "2000"], ["Nateglinide is safe and efficacious in lowering postprandial blood glucose in type 2 diabetic patients with various degree of renal function", "2001"], ["Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency", "2000"], ["Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus", "2001"], ["Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus", "2000"], ["Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying Out or Commissioning Reviews", "2000"], ["Insulin treatment after 3 years in patients with type 2 diabetes following participation in a study of combination regimes of insulin, repaglinide and metformin", "2005"], ["Nateglinide has a low hypoglycemic potential in a missed\u2010meal situation", "2000"], ["Nateglinide is effective and safe in elderly patients with Type 2 diabetes", "2000"], ["Risk of delayed hypoglycemia is reduced with nateglinide compared to repaglinide", "2000"], ["The improvement of early phase of insulin secretion after glucose load with nateglinide in patients with type 2 diabetes", "2001"], ["Multiple effects of Nateglinide on glucose metabolism in obese patients with type 2 diabetes mellitus", "2002"], ["Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes", "2000"], ["Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes", "2000"], ["Comparison of effects of repaglinide and nateglinide on insulin secretion and postloading glucose excursions in patients with Type 2 diabetes", "2002"], ["Comparison of effects of repaglinide and nateglinide on insulin secretion and postloading glucose excursions in patients with type 2 diabetes", "2003"], ["Efficacy of repaglinide vs. nateglinide: As monotherapy or metformin combination therapy", "2002"], ["Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double\u2010blind study with repaglinide", "2002"], ["Single\u2010 and multiple\u2010dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment", "2001"], ["Repaglinide in type 2 diabetes: A randomized, double\u2010blind, placebo\u2010controlled, dose\u2010response study", "1998"], ["3 year follow up of a randomised controlled trial of combination regimes of insulin, repaglinide and metformin in people with type 2 diabetes mellitus", "2005"], ["Pharmacokinetics, pharmacodynamics, and dose\u2010response relationship of repaglinide in type 2 diabetes", "1999"], ["Efficacy and safety of nateglinide in patients with mild hyperglycaemia", "2001"], ["Repaglinide plus bedtime insulin is as effective as premixed insulin twice daily but more safe than insulin alone in Type 2 diabetes mellitus inadequately controlled with oha therapy", "2002"], ["Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide", "2000"], ["The impaired acute insulin response in newly diagnosed Type 2 diabetic patients can be restored by nateglinide and repaglinide", "2004"], ["Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus", "2000"]], "in": [["Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus\u2010\u2010a randomized study using positron emission tomography", "2005"], ["Effect of a prandial glucose regulator (NovoNorm) at two doses (0.5 mg and 2 mg) on glycemic control in type 2 diabetes in Taiwan", "1999"], ["Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin", "2003"], ["Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy", "2002"], ["A randomized placebo\u2010controlled trial of repaglinide in the treatment of type 2 diabetes", "1998"], ["Rapid and short\u2010acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia", "2000"], ["Both nateglinide and metformin sustain HbA(1c) lowering over 52 weeks in drug\u2010naive type 2 diabetes patients", "2003"], ["Repaglinide in type 2 diabetes: a 24\u2010week, fixed\u2010dose efficacy and safety study", "2000"], ["Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients", "2002"], ["Repaglinide in combination therapy with metformin in Type 2 diabetes", "1999"], ["The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy\u2010naive Type 2 diabetes: A placebo\u2010 controlled, multicentre study", "2003"], ["Efficacy and Safety of Combination Therapy: Repaglinide plus metformin versus nateglinide plus metformin", "2003"], ["Repaglinide versus nateglinide monotherapy: a randomized, multicenter study", "2004"], ["Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia", "2002"], ["Repaglinide improves blood glucose control in sulphonylurea\u2010naive type 2 diabetes", "2001"]]}